We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a ...

Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome dysfunction and has initiated dosing in the SAD cohort of the phase 1 clinical trial ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease ...

(RTTNews) - Arvinas Inc. (ARVN), a clinical-stage biotechnology company, Friday announced promising first-in-human data for ARV-102, an investigational oral PROTAC designed to target and degrade ...

Arv­inas re­port­ed ear­ly-stage da­ta for its PRO­TAC pro­gram in healthy vol­un­teers, hop­ing the re­sults will even­tu­al­ly trans­late to pa­tients with Parkin­son’s dis­ease.